CHEMOCENTRYX INC (CCXI)
US16383L1061 - Common Stock
Overall CCXI gets a fundamental rating of 3 out of 10. We evaluated CCXI against 588 industry peers in the Biotechnology industry. CCXI may be in some trouble as it scores bad on both profitability and health. CCXI is valued quite expensive, but it does show an excellent growth.
1. Profitability
1.1 Basic Checks
CCXI had negative earnings in the past year.
CCXI had a negative operating cash flow in the past year.
CCXI had negative earnings in 4 of the past 5 years.
In multiple years CCXI reported negative operating cash flow during the last 5 years.
1.2 Ratios
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -31.74% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | -353.17% | ||
| PM (TTM) | -357.01% | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
CCXI does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CCXI has been increased compared to 1 year ago.
The debt/assets ratio for CCXI is higher compared to a year ago.
2.2 Solvency
CCXI has an Altman-Z score of 9.70. This indicates that CCXI is financially healthy and has little risk of bankruptcy at the moment.
A Debt/Equity ratio of 0.02 indicates that CCXI is not too dependend on debt financing.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 9.7 |
ROIC/WACCN/A
WACC9.62%
2.3 Liquidity
CCXI has a Current Ratio of 4.54. This indicates that CCXI is financially healthy and has no problem in meeting its short term obligations.
A Quick Ratio of 4.47 indicates that CCXI has no problem at all paying its short term obligations.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.54 | ||
| Quick Ratio | 4.47 |
3. Growth
3.1 Past
CCXI shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -6.78%.
The Revenue has grown by 72.49% in the past year. This is a very strong growth!
CCXI shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 21.96% yearly.
EPS 1Y (TTM)-6.78%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q21.43%
Revenue 1Y (TTM)72.49%
Revenue growth 3Y-9.08%
Revenue growth 5Y21.96%
Revenue growth Q2Q548.81%
3.2 Future
Based on estimates for the next years, CCXI will show a very strong growth in Earnings Per Share. The EPS will grow by 47.34% on average per year.
CCXI is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 134.59% yearly.
EPS Next Y9.69%
EPS Next 2Y37.13%
EPS Next 3Y41.06%
EPS Next 5Y47.34%
Revenue Next Year117.77%
Revenue Next 2Y157.52%
Revenue Next 3Y130.02%
Revenue Next 5Y134.59%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
CCXI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CCXI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | -26.68 |
4.3 Compensation for Growth
A more expensive valuation may be justified as CCXI's earnings are expected to grow with 41.06% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y37.13%
EPS Next 3Y41.06%
5. Dividend
5.1 Amount
No dividends for CCXI!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CHEMOCENTRYX INC
NASDAQ:CCXI (10/19/2022, 7:04:24 PM)
After market: 51.99 0 (0%)51.99
+0.03 (+0.06%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap3.71B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -31.74% | ||
| ROE | N/A | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | -353.17% | ||
| PM (TTM) | -357.01% | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.09
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 4.54 | ||
| Quick Ratio | 4.47 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-6.78%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y9.69%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)72.49%
Revenue growth 3Y-9.08%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y